Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.32 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.32 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.32 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.32 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.32 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28714893 | 1.00 | SPHK1 (0.32) | SPHK1CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL28130926 | 0.83 | SPHK1 (0.31) | SPHK1 | |
| SCHEMBL23850149 | 0.82 | SPHK1 (0.35) | SPHK1 | |
| SCHEMBL3633420 | 0.82 | SPHK1 (0.35) | SPHK1 | |
| SCHEMBL23850147 | 0.82 | SPHK1 (0.35) | SPHK1 | |
| SCHEMBL4912532 | 0.82 | SPHK1 (0.35) | SPHK1 | |
| SCHEMBL15318921 | 0.82 | SPHK1 (0.35) | SPHK1 | |
| SCHEMBL19733005 | 0.79 | SPHK1 (0.33) | SPHK1 | |
| SCHEMBL16559002 | 0.79 | — | — | |
| SCHEMBL15318889 | 0.79 | SPHK1 (0.54) | SPHK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114591223-A | Beta-lactamase inhibitor compounds | 恩塔西斯治疗有限公司 | 2022-06-07 | — | — | CN | disclosed |
| CN-109715630-B | Beta-lactamase inhibitor compounds | 恩塔西斯治疗有限公司 | 2022-02-22 | — | — | CN | disclosed |
| EP-2834239-B1 | HETEROBICYCLIC COMPOUNDS AS BETA-LACTAMASE INHIBITORS | ENTASIS THERAPEUTICS LTD (GB) | 2017-12-27 | — | — | EP | disclosed |
| CN-104364254-B | Heterobicyclic compounds as beta-lactamase inhibitors | 恩塔西斯治疗有限公司 | 2017-02-22 | — | — | CN | disclosed |